61-75 of 88
Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
MinuteCE®Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD
ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
MinuteCE®ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD
Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
MinuteCE®Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD
Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC
MinuteCE®Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD
The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC
MinuteCE®The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD
Chairperson’s Perspective: Treating At-Risk MASH: What Are You Waiting For?
CME/CEChairperson’s Perspective: Treating At-Risk MASH: What Are You Waiting For?
Mazen Noureddin, MD, MHSc
- advertisement
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
CME/CEAdvances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Naim Alkhouri, MD, FAASLD, DABOM
The Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care – Chair’s Perspective
CME/CEThe Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care – Chair’s Perspective
Naim Alkhouri, MD, FAASLD, DABOM
Advances in the Treatment and Management of MASH: More Options, More Decisions
CME/CE Broadcast ReplayAdvances in the Treatment and Management of MASH: More Options, More Decisions
Mary E. Rinella, MD, FAASLD
Naga Chalasani, MD, FAASLD
Mazen Noureddin, MD, MHSc
Practical Management of Variceal Bleeding and Hepatorenal Syndrome
CME/CEPractical Management of Variceal Bleeding and Hepatorenal Syndrome
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Andrew Keaveny, MD
Don Rockey, MD
Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Marlyn Mayo, MD
Atoosa Rabiee, MD
Primary Biliary Cholangitis: The Phenotype, It Is a Changin'
MinuteCE®Primary Biliary Cholangitis: The Phenotype, It Is a Changin'
Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Atoosa Rabiee, MD
- advertisement
Primary Biliary Cholangitis vs Primary Sclerosing Cholangitis: Do You Know the Difference?
MinuteCE®Primary Biliary Cholangitis vs Primary Sclerosing Cholangitis: Do You Know the Difference?
Marlyn Mayo, MD
Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Primary Biliary Cholangitis: A Natural History Lesson
MinuteCE®Primary Biliary Cholangitis: A Natural History Lesson
Marlyn Mayo, MD
Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Atoosa Rabiee, MD
